Across TCGA pan-cancer cohorts, MYL5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYL5 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MYL5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYL5 expression acts as an unfavorable survival marker.

ESCA, TGCT, and SKCM are the cancer types where MYL5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.089	0.522	.001	12	view →
TGCT	DFS	Median	All	0.094	0.801	.008	6	view →
SKCM	OS	Median	All	0.340	0.786	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MYL5 tumor-vs-normal RNA expression · all MYL5 data types